Want to see CLLS full AI Analyst Report?
Top Page
Cellectis SA
(NASDAQ:CLLS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-70.76% Downside)
Action:Upgraded
Date:10/29/26
The score is primarily held down by weak financial performance: persistent heavy losses, renewed cash burn, and a more leveraged balance sheet with materially reduced equity. Technicals add further pressure due to a clear downtrend and negative MACD, though near-oversold RSI/Stoch modestly temper the bearish setup. Valuation is difficult to support with a negative P/E and no dividend yield provided.
Positive Factors
Gene-editing pipeline expansion
The .HEAL-101 results broaden Cellectis’s opportunity beyond oncology into in vivo cardiometabolic gene editing. Strong editing and biomarker changes in preclinical models support continued development and a planned Phase 1 trial, potentially adding a differentiated growth avenue over the next several years.
Negative Factors
Persistent unprofitability
Large operating and net losses show that the current business model has not yet reached economic scale. Continued losses can consume capital, limit strategic flexibility, and require successful clinical progress or partnering to convert the platform into sustainable earnings over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Gene-editing pipeline expansion
The .HEAL-101 results broaden Cellectis’s opportunity beyond oncology into in vivo cardiometabolic gene editing. Strong editing and biomarker changes in preclinical models support continued development and a planned Phase 1 trial, potentially adding a differentiated growth avenue over the next several years.
Read all positive factors
Cellectis SA (CLLS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$90.97M
Dividend YieldN/A
Average Volume (3M)154.43K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth-0.11%
EPS Growth-13.99%
CountryUS
Employees229
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.66
Shares Outstanding72,325,455
10 Day Avg. Volume131,307
30 Day Avg. Volume154,429
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)6.39
Price to Sales (P/S)6.65
P/FCF Ratio-11.42
Enterprise Value/Market Cap2.63
Enterprise Value/Revenue4.23
Enterprise Value/Gross Profit5.66
Enterprise Value/Ebitda-4.31
Forecast
1Y Price Target
$4.10Price Target Upside19.88% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$53.56M
Cellectis SA Business Overview & Revenue Model
Company Description
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifi...
How the Company Makes Money
Cellectis primarily seeks to generate value and revenue through the development and commercialization (directly or via partners) of its gene-edited allogeneic cell therapy candidates. In practice, as a clinical-stage biotech, its cash inflows are ...
Cellectis SA Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The earnings call reflects a generally positive sentiment, driven by progress in clinical trials and strategic partnerships, despite financial and legal challenges. The successful advancement of pivotal trials and the strong collaboration with AstraZeneca are significant positives. However, the arbitration with Servier presents a notable uncertainty.Positive Updates
Pivotal Phase II Trial Initiation
Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Negative Updates
Servier Arbitration Uncertainty
Cellectis is involved in ongoing arbitration with Servier and Allogene, seeking to terminate the agreement and receive compensation for losses and milestone payments due to halted CD19 product development.
Read all updates
Q2-2025 Updates
Positive
Negative
Pivotal Phase II Trial Initiation
Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Read all positive updates
Company Guidance
During the Cellectis Second Quarter 2025 Earnings Call, the company provided extensive guidance on several key metrics and strategic initiatives. Cellectis announced plans to host an Investor R&D Day on October 16, 2025, in New York City, where they will present Phase I data and a late-stage development strategy for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia. The pivotal Phase II trial for lasme-cel is set to begin in the second half of 2025, following productive discussions with the FDA and EMA. The company also updated on their arbitration proceedings with Servier, with a decision expected by December 15, 2025. Financially, Cellectis reported a cash position of $230 million as of June 30, 2025, sufficient to fund operations into the second half of 2027. This includes the costs associated with the pivotal studies for lasme-cel and eti-cel. Additionally, the company shared progress on their collaboration with AstraZeneca, which includes three cell and gene therapy programs.Cellectis SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
35
Negative
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.59M | 72.95M | 41.51M | 755.00K | 19.17M | 30.35M |
| Gross Profit | 42.27M | 63.15M | 32.32M | -6.66M | 10.69M | 28.50M |
| EBITDA | -55.48M | -39.85M | -9.46M | -92.64M | -76.38M | -78.42M |
| Net Income | -65.35M | -67.59M | -36.76M | -101.06M | -106.14M | -114.20M |
Balance Sheet | ||||||
| Total Assets | 267.37M | 324.72M | 383.54M | 334.27M | 261.22M | 382.08M |
| Cash, Cash Equivalents and Short-Term Investments | 166.85M | 208.66M | 260.31M | 203.81M | 97.70M | 186.13M |
| Total Debt | 84.57M | 119.90M | 91.46M | 85.06M | 75.77M | 100.87M |
| Total Liabilities | 226.30M | 248.82M | 252.51M | 249.57M | 135.28M | 145.60M |
| Stockholders Equity | 41.07M | 75.90M | 131.03M | 84.69M | 117.97M | 221.29M |
Cash Flow | ||||||
| Free Cash Flow | -44.06M | -42.50M | 19.52M | -25.82M | -89.89M | -123.12M |
| Operating Cash Flow | -41.89M | -40.14M | 22.10M | -24.75M | -87.44M | -104.56M |
| Investing Cash Flow | 31.66M | -29.58M | -102.63M | -15.51M | -2.76M | 7.28M |
| Financing Cash Flow | -16.37M | -16.20M | 89.80M | 82.86M | 1.15M | 47.52M |
Cellectis SA Technical Analysis
Neutral
3.42
Price Trends
1.98
Negative
2.45
Negative
3.10
Negative
Market Momentum
-0.22
Negative
45.51
Neutral
64.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Neutral. The current price of 3.42 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.98, and above the 200-day MA of 3.10, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 45.51 is Neutral, neither overbought nor oversold. The STOCH value of 64.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLLS.
Cellectis SA Risk Analysis
Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cellectis SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $419.02M | -3.88 | -53.97% | ― | ― | -76.37% | |
44 Neutral | $90.97M | -1.92 | -94.14% | ― | -0.11% | -13.99% | |
44 Neutral | $202.41M | -1.13 | 141.41% | ― | ― | ― | |
42 Neutral | $126.49M | -2.15 | 72.64% | ― | 51.98% | 17.68% | |
41 Neutral | $1.22B | 0.11 | -91.63% | ― | ― | 69.48% | |
40 Underperform | $92.04M | -0.76 | -108.05% | ― | ― | 45.08% |
* Healthcare Sector Average
CLLS
Cellectis SA
1.26
-2.37
-65.29%
RNAC
Cartesian Therapeutics
6.69
-1.51
-18.41%
FHTX
Foghorn Therapeutics
2.13
-2.10
-49.65%
VOR
Vor Biopharma
20.65
-4.85
-19.02%
TNYA
Tenaya Therapeutics
0.40
-1.03
-71.82%
ZURA
Zura Bio
4.35
0.57
15.08%
Cellectis SA Corporate Events
Cellectis Showcases Strong Preclinical Data for APOC3 Base Editor .HEAL-101 at ESGCT 2026
Oct 28, 2026
On October 27, 2026, Cellectis reported new preclinical data for .HEAL-101, an in vivo TALE base-editing therapy targeting APOC3 for severe hypertriglyceridemia, presented at the ESGCT congress in Hamburg. In human liver cell lines and humanized m...
Cellectis Plans Heavy Investor Conference Schedule for Fall 2026
Sep 1, 2026
On September 1, 2026, Cellectis announced that it would engage actively with the investment community through a series of healthcare conferences in the U.S. and Europe in the fourth quarter of 2026. The company plans to attend events hosted by Wel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.